Cargando…
A screen to identify drug resistant variants to target-directed anti-cancer agents
The discovery of oncogenes and signal transduction pathways important for mitogenesis has triggered the development of target-specific small molecule anti-cancer compounds. As exemplified by imatinib (Gleevec), a specific inhibitor of the Chronic Myeloid Leukemia (CML)-associated Bcr-Abl kinase, the...
Autores principales: | Azam, Mohammad, Raz, Tal, Nardi, Valentina, Opitz, Sarah L., Daley, George Q. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC248481/ https://www.ncbi.nlm.nih.gov/pubmed/14615817 http://dx.doi.org/10.1251/bpo63 |
Ejemplares similares
-
Bone marrow adipocytes as negative regulators of the hematopoietic microenvironment
por: Naveiras, Olaia, et al.
Publicado: (2009) -
Anti-angiogenic drugs: direct anti-cancer agents with mitochondrial mechanisms of action
por: Quayle, Lewis A., et al.
Publicado: (2017) -
iPSC screening for drug repurposing identifies anti‐RNA virus agents modulating host cell susceptibility
por: Imamura, Keiko, et al.
Publicado: (2021) -
Direct anti-HCV agents
por: Zhang, Xingquan
Publicado: (2016) -
Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple sulfatase deficiency
por: Schlotawa, Lars, et al.
Publicado: (2023)